Skip to main content
IRWD
NASDAQ Life Sciences

Director-affiliated entity sells over $20.5M in Ironwood Pharmaceuticals stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.23
Mkt Cap
$529.94M
52W Low
$0.527
52W High
$5.78
52W Position info
513% above low
Off High info
44% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

IRWD has more than doubled off its 52-week low of $0.527 on elevated volume (2.3× avg).

Summary

A director-affiliated investment firm sold over $20.5 million worth of Ironwood Pharmaceuticals stock, representing a substantial reduction in its holdings.


Key Events · Ownership and Investor Activity · IRWD

  • Significant Stock Sale by Director-Affiliated Entity

    Alexander J. Denner, a Director and CIO of Sarissa Capital Management LP, reported the sale of 6,730,800 shares of Class A Common Stock for $20,530,448. The shares were held indirectly by Sarissa Capital and its funds.

  • Substantial Reduction in Holdings

    This transaction represents a significant reduction in the holdings of a key institutional investor affiliated with a company director, accounting for 3.874% of Ironwood Pharmaceuticals' market capitalization.

  • Routine Equity Grant

    Separately, Mr. Denner also received a grant of 4,451 shares of Class A Common Stock on March 13, 2026, as part of the non-employee director compensation policy, valued at $0.


Analysis · IRWD · Life Sciences

Alexander J. Denner, a Director of Ironwood Pharmaceuticals and Chief Investment Officer of Sarissa Capital Management LP, reported the sale of 6,730,800 shares of Class A Common Stock for a total value of $20,530,448. This significant sale, representing 3.874% of the company's market capitalization, is an institutional disposition by Sarissa Capital. While such sales can be for portfolio rebalancing, the substantial size indicates a notable reduction in exposure by a key affiliated entity. This transaction reinforces a pattern of net insider distribution over the last 90 days.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IRWD was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $529.9M. The 52-week trading range was $0.53 to $5.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IRWD - Latest Insights

IRWD
Nov 05, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $4.68 info
Change: +$0.640 (+16%) info
Market Cap: $791.333M info
IRWD
Nov 05, 2026, 7:54 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $4.68 info
Change: +$0.545 (+13%) info
Market Cap: $791.333M info
IRWD
Nov 05, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $4.68 info
Change: +$0.430 (+10%) info
Market Cap: $791.333M info
IRWD
Nov 05, 2026, 7:05 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.78
Real-time Price: $4.68 info
Change: +$0.900 (+24%) info
Market Cap: $791.333M info
IRWD
Oct 16, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.78
Real-time Price: $4.68 info
Change: +$0.900 (+24%) info
Market Cap: $791.333M info